Merck KGaA Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Merck KGaA yıllık ortalama 16.5% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 13.1% annual. Gelirler growing yılda ortalama 7.2% oranında artmaktadır. Merck KGaA'in özkaynak karlılığı 9.2% ve net marjı 12.6%'dir.

Anahtar bilgiler

16.5%

Kazanç büyüme oranı

16.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	7.3%
Gelir büyüme oranı	7.2%
Özkaynak getirisi	9.2%
Net Marj	12.6%
Sonraki Kazanç Güncellemesi	14 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

Mar 26

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20

Mar 05

Estimating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Feb 14

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Stay On Top Of Its Debt

Dec 12

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Trading At A 50% Discount?

Nov 09

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

Aug 15

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

May 17

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €1.85

Mar 29

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Risky Investment?

Jan 13

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Manage Its Debt With Ease

Oct 15

A Look At The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Sep 19

Gelir ve Gider Dağılımı

Merck KGaA nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

XTRA:MRK Gelir, gider ve kazançlar (EUR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	20,870	2,626	5,735	2,469
31 Mar 24	20,820	2,722	5,738	2,423
31 Dec 23	20,993	2,824	5,786	2,439
30 Sep 23	21,428	2,893	5,823	2,398
30 Jun 23	22,061	3,078	6,035	2,460
31 Mar 23	22,327	3,242	6,075	2,458
31 Dec 22	22,232	3,326	5,982	2,447
30 Sep 22	21,785	3,473	5,925	2,411
30 Jun 22	20,952	3,311	5,745	2,436
31 Mar 22	20,254	3,188	5,557	2,428
31 Dec 21	19,687	3,055	5,461	2,418
30 Sep 21	19,072	2,689	5,334	2,466
30 Jun 21	18,546	2,733	5,234	2,330
31 Mar 21	17,795	2,278	5,230	2,259
31 Dec 20	17,534	1,987	5,300	2,262
30 Sep 20	17,317	1,884	5,453	2,231
30 Jun 20	16,924	1,419	5,550	2,258
31 Mar 20	16,776	1,549	5,643	2,291
31 Dec 19	16,152	1,292	5,669	2,239
30 Sep 19	15,658	1,139	5,646	2,276
30 Jun 19	15,354	1,118	5,640	2,260
31 Mar 19	15,096	938	5,597	2,245
31 Dec 18	14,836	1,071	5,501	2,226
30 Sep 18	14,597	1,921	5,166	2,157
30 Jun 18	14,364	2,218	5,065	2,152
31 Mar 18	14,346	2,389	5,054	2,127
31 Dec 17	14,517	2,548	5,088	2,107
30 Sep 17	14,699	1,787	5,454	2,085
30 Jun 17	14,906	1,628	5,497	1,991
31 Mar 17	15,016	1,529	5,448	1,975
31 Dec 16	15,024	1,629	5,432	1,976
30 Sep 16	14,658	1,480	5,292	1,824
30 Jun 16	14,054	1,387	5,122	1,798
31 Mar 16	13,469	1,418	5,000	1,757
31 Dec 15	12,845	1,109	4,816	1,709
30 Sep 15	12,380	1,269	4,613	1,738
30 Jun 15	12,180	1,154	4,515	1,826
31 Mar 15	11,776	1,114	4,377	1,765
31 Dec 14	11,363	1,157	4,253	1,704
30 Sep 14	11,106	1,158	4,060	1,627
30 Jun 14	10,937	1,249	4,301	1,501
31 Mar 14	10,963	1,261	3,992	1,480
31 Dec 13	11,095	1,202	3,705	1,507

Kaliteli Kazançlar: MRK yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: MRK 'nin mevcut net kar marjları (12.6%) geçen yılın (14%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: MRK şirketinin kazancı son 5 yılda yılda 16.5% oranında arttı.

Büyüme Hızlandırma: MRK 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: MRK geçtiğimiz yıl negatif kazanç büyümesine ( -14.7% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( 28.7% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: MRK 'nin Özsermaye Getirisi ( 9.2% ) düşük olarak değerlendiriliyor.

Merck KGaA Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

First quarter 2024 earnings: EPS exceeds analyst expectations

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Second quarter 2023 earnings: Revenues exceed analyst expectations

Recent updates

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Some Shareholders Feeling Restless Over Merck KGaA's (ETR:MRK) P/E Ratio

Is There An Opportunity With Merck KGaA's (ETR:MRK) 44% Undervaluation?

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Here's Why Merck KGaA (ETR:MRK) Can Manage Its Debt Responsibly

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Some Confidence Is Lacking In Merck KGaA's (ETR:MRK) P/E

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 48% Above Its Share Price

First quarter 2024 earnings: EPS exceeds analyst expectations

Merck KGaA, Annual General Meeting, Apr 25, 2025

Merck KGaA (ETR:MRK) Will Pay A Dividend Of €2.20

Upcoming dividend of €2.20 per share

Merck KGaA (ETR:MRK) Is Paying Out A Dividend Of €2.20

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Merck KGaA (ETR:MRK) Has Affirmed Its Dividend Of €2.20

Dividend of €2.20 announced

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt

There's Reason For Concern Over Merck KGaA's (ETR:MRK) Price

Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 77% Above Its Share Price

Investor sentiment deteriorates as stock falls 15%

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Does Merck KGaA (ETR:MRK) Have A Healthy Balance Sheet?

Is There An Opportunity With Merck KGaA's (ETR:MRK) 49% Undervaluation?

Second quarter 2023 earnings: Revenues exceed analyst expectations

Merck KGaA, Annual General Meeting, Apr 26, 2024

Is Merck KGaA (ETR:MRK) A Risky Investment?

Are Investors Undervaluing Merck KGaA (ETR:MRK) By 36%?

First quarter 2023 earnings: Revenues in line with analyst expectations

Merck Announces CFO Changes

Upcoming dividend of €2.20 per share at 1.3% yield

These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20

Full year 2022 earnings: Revenues in line with analyst expectations

Estimating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Now 21% undervalued

Now 21% undervalued

Now 21% undervalued

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Stay On Top Of Its Debt

Third quarter 2022 earnings: Revenues exceed analyst expectations

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Trading At A 50% Discount?

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: Revenues exceed analyst expectations

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of €1.85 per share

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €1.85

Full year 2021 earnings: Revenues in line with analyst expectations

MERCK Kommanditgesellschaft auf Aktien to Report Q2, 2022 Results on Aug 04, 2022

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Risky Investment?

Third quarter 2021 earnings released

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Manage Its Debt With Ease

A Look At The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Price target increased to €195

Price target increased to €170

Second quarter 2021 earnings released: EPS €1.71 (vs €0.67 in 2Q 2020)

Head of Oncology Development Klaus Edvardsen has left the company